The global cancer pain market is expected to post a healthy market growth rate during the forecast period. The steady growth of this market can be attributed to the launch of new products that specifically treat pain-related to cancer. Pain in cancer may come from compressing or infiltrating nearby body parts, from treatments and diagnostic procedures or from the skin, nerve, and the other changes caused by a hormone imbalance or immune response.
Most chronic pain is caused by the illness and most acute pain is caused by the treatment or diagnostic procedures. The radiotherapy and chemotherapy may produce painful conditions that persist long after treatment has ended. The presence of pain depends mainly on the location of cancer and the stage of the disease. At any given time with malignant cancer smacks pain, and two-thirds of those with advanced cancer experience pain of such intensity that it adversely affects their sleep, mood, social relation, and activities of daily living.
Cancer Pain Market by Drug-Class: Opioids, Non-steroidal anti-inflammatory drugs, others.
Non-steroidal anti-inflammatory drugs block the production of prostaglandins by inhibiting the cyclooxygenase enzyme and therefore, reduce the pain at the site of injury. The NSAIDs are drug class that groups together drugs that provide analgesic and antipyretic effects, and in higher doses, anti-inflammatory effects.
Aspirin-like drugs: These medications are used for bone pain, and pain caused by inflammation. Some people experience stomach problems such as indigestion and bleeding with this type of medication. Aspirin itself is generally avoided; because it is too hard on the stomach if taken regularly.
Paracetamol is important in cancer pain control. It is usually well-tolerated; doesn’t affect the stomach and won’t thin the blood. It is helpful to reduce fever and relieve bone pain and is often used along with opioids.
Opioids act on ovoid receptors to produce morphine-like effects. Opioids are used most often to relieve pain. Opioids are semi-synthetic and synthetic drugs such as hydrocodone, oxycodone, and fentanyl antagonist drugs such as naloxone and endogenous peptides such as the endorphins.
Cancer Pain Market by Treatment: Immunotherapy, which may produce joint or muscle pain; Radiotherapy, which can cause skin reactions, enteritis, fibrosis, myelopathy, bone necrosis, neuropathy; Chemotherapy, which is often associated with chemotherapy include peripheral neuropathy, mucositis, joint pain, muscle pain, and abdominal pain due to diarrhea.
Hormone therapy: This sometimes causes pain flares. Targeted Therapies, such as trastuzumab and rituximab can cause muscle, joint, or chest pain; Angiogenesis inhibitors, like bevacizumab, known to sometimes cause bone pain; and Surgery, which may produce postoperative pain, post-amputation pain or pelvic floor myalgia.
Cancer Pain Market by Treatment Choice: The location of the pain, The severity of the pain, The type of pain such as sharp, tingling or aching, whether the pain is persistent, or comes and goes, what activities or events make the pain worse, what activities or events make the pain better, current medications, how much current medications ease the pain, the impact the pain has on lifestyle, such as poor quality of sleep or loss of appetite.
Cancer Pain Market by Geographical Regions: North America: U.S., Canada, Europe: France, Germany, Italy, Spain, and England, APAC: China, India, Japan, Australia, Others, Latin America: Argentina, Brazil, Others.
The Key Players include BioDelivery Science, ProStrakan Group, Teva pharmaceuticals, Daiichi Sankyo, Eli-Lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, WEX Pharmaceuticals.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.